Ross now serves as Deputy President overseeing H3 business functions. Ross joined H3 in Feb 2018 as Vice President of Clinical Operations providing leadership in the Clinical Development team for the planning and execution of H3’s portfolio of target-centric precision oncology medicines. Ross brings more than 30 years of extensive drug development experience to H3. He has focused his career in clinical operations, regulatory affairs, and alliance and portfolio management. During that time Ross has been a key contributor in bringing multiple new drugs to market, across a number of therapeutic areas, and engaging in multiple strategic development alliances and partnerships. Ross has worked extensively in the Americas, Europe and Asia and has held leadership positions with companies including Otsuka, EMD Serono, Coley, ARIAD, AMAG, Infinity and Beigene.

Ross earned an M.B.A. in HealthCare Management from the University of Phoenix and a B.Sc. (Hons) from the University of Kingston, London.